LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech ...

Despite multiple treatments for eczema and pityriasis alba, a child’s skin condition worsened until a biopsy revealed mycosis ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...

Corvus Pharmaceuticals reported positive Phase 1/1b trial data for soquelitinib in T cell lymphoma, showing significant anti-tumor activity. Corvus Pharmaceuticals, Inc. announced new findings ...

The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an ...

Researchers Uncover Mechanism That Fuels Growth of Aggressive B-Cell Lymphoma June 18 ... Details About Rare Second Cancers Related to CAR-T Therapy June 12, 2024 — A new detailed analysis ...

Bi-Specific 3rd Generation CAR T therapy is a revolutionary advancement in cellular immunotherapy, primarily used to treat ...

INAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc ...